A Phase II clinical trial showed good response in combination chemotherapy with gemcitabine for advanced pancreatic cancer. However, Pfizer reported on January 30, 2009 that Phase III clinical trials of the drug when used in combination with gemcitabine showed no evidence of improved survival rates over treatments using gemcitabine alone for advanced pancreatic cancer and halted the trial. In 2010, a Phase III trial for previously treated metastatic renal cell carcinoma (mRCC) showed significantly extended progression-free survival when compared to sorafenib. In December 2011, the Oncologic Drugs Advisory Committee (ODAC) voted unanimously to recommend that US FDA approve<unk>  for the second-line treatment of patients with advanced renal cell carcinoma (RCC), based on the results of the Phase III trial comparing<unk>  and sorafenib. It has also been studied in combination with the ALK1 inhibitor dalantercept. A study published in 2015 showed that<unk>  effectively inhibits a mutated gene (BCR-ABL1T315I) that is common in chronic myeloid leukemias and adult acute lymphoblastic leukemias which have become resistant to other tyrosine kinase inhibitors like imatinib. This is one of the first examples of a new indication for an existing drug being discovered by screening known drugs using a patient's own cells.
Axitinib
Ceritinib
Abrocitinib
Upadacitinib
Sunitinib
Afatinib
Erdafitinib
Dacomitinib